Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on DANIELI & CO. We currently have 5 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
DANIELI & CO
DANIELI & CO
FY15/16 results : disappointing
28 Sep 16
Danieli released FY15/16 results (closing 30 June). Revenues reached €2,508.4m (-9%), EBITDA €211.4m (-17%), EBIT €90.2m (-40%) and the net result €88.3m (-45%). The order book at the end of June reached €2,814m (-5%). The group’s net cash at the end of fiscal 2015/16 stood at €908m (-5%). A dividend of €0.10 per share (€0.1207 for savings shares) will be proposed at the group’s AGM on 28 October.
Q3 16: the same trend as in H1
12 May 16
Danieli released 9 months figures. Revenues reached €1,691.3m (-15%), EBITDA €154m (-11%), EBIT €78.3m (-22%) and net income €54m (-54%). Net cash at the end of March 2016 amounted to €823.5m (vs €841.8m at the end of H1 and €956m a year before). The group’s order book stood at €2,975m (vs €3,026m in December and €3,155m at the end of the last fiscal year.
H1 15/16: in line
26 Feb 16
Danieli’s H1 15/16 results were released. Revenues reached €1,161.1m (-14%), EBITDA €108.4m (-14%), EBIT €55.4m (-30%) and net profit €45m (-32%). Net cash at the end of H1 was €841.8m (vs €956m at year end 14/15 and €881m in Q1). The group’s order book stood at €3,026m (vs €3,155m in June 2015 and €3,094m at the end of Q1). The group confirms the FY16 results should be in line with the forecasts made at the beginning of the year (i.e. revenues of €2,700-2,850m and an EBITDA of €240-260m).
Q1 15/16: signs of weakness
13 Nov 15
Danieli released Q1 15/16 results (as at 30 September 2015). Sales reached €556m (-15% yoy), EBITDA €51.6m (-22% yoy), EBIT €28.1m (-35% yoy) and the net result €22.5m (-58% yoy). Net cash at the end of Q1 15/16 was €880.5m (8% down from €956m at year end 2014/15). The group’s order book stood at €3,094m (-2% qoq, of which -9% in Steel Making to €154m).
FY14/15 in line. Dividend cut and no outlook (yet) released for 2015/16
25 Sep 15
Danieli released its FY14/15 results. Revenues reached €2,765.9m (-6%), EBITDA €250.5m (-19%), EBIT €150.2m (-29%) and the net result (group share) €161.8m (+5%). Net cash at the end of the year reached €956m (vs €844.3m a year before) and the order book €3,155m (+2% yoy and +15% sequentially). The company will cut its dividend to €0.10 (vs €0.30 last year), reducing its pay-out from 13-15% historically to a mere 5%.
20 Feb 17
Hayward Tyler Group* (HAYT): Trading update and financial position (CORP) | Petra Diamonds (PDL): Interim results (BUY) | Gemfields* (GEM): Interim results (CORP) | Premaitha Health* (NIPT): Middle East momentum (CORP) | Sound Energy (SOU): Acquisition update and TE-8 well spud (HOLD) | Proactis* (PHD): Interim trading on track (CORP) | 7digital* (7DIG): Automotive contract win (CORP)
The Slide Rule
12 Jan 17
What is The Slide Rule? The Slide Rule has been designed to dramatically simplify the identification of the best companies in the UK small/mid-cap sector by making a quantitative assessment of the relative potential of each company. At its core, The Slide Rule aims to identify those companies that create genuine shareholder value through strong returns on capital and solid growth, but also present a value opportunity with the potential tailwind of earnings momentum. Companies are assessed within a Quality, Value, Growth and Momentum (QVGM) framework.
21 Feb 17
Lighthouse Group* (LGT): Middle Britain growth (CORP) | Utilitywise* (UTW): Double-digit sales growth (CORP) | Trakm8* (TRAK): Earnings expectations cut again (CORP) | dotDigital* (DOTC): Myriad growth opportunities (CORP) | Artilium* (ARTA): Five-year Telenet deal secured and prepaid (CORP) | Netcall* (NET): Cloud investment pays off (CORP)
N+1 Singer - Small-cap quantitative research - New quality style screen + 11 quality focus stocks
09 Feb 17
We introduce our fourth and final style screen representing “quality”. This screens for stocks with the best combination of high returns on capital/equity, EBIT margins and operating cash-flow conversion rates. These criteria should help us monitor how strong underlying returns translate into share price performance over time and under varying market conditions. The screen selects the “best” 25 stocks from our universe of just over 500 stocks and, as usual, we focus on a shorter list of stocks we cover or otherwise know and believe to be particularly interesting. We provide brief investment summaries on these focus stocks on pages 4 – 9. We will monitor performance and refresh the screen in approximately 3-4 months time.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced
Small Cap Breakfast
16 Feb 17
Saffron Energy—Schedule One update. Raising £2.5m, expected Mkt Cap £7.7m. Admission due 24 Feb. Italian Oil & Gas Play Guinness Oil & Gas Exploration—Publication of prospectus. Seeking to raise £50m and invest in 15 exploration companies at launch, with plans to grow the portfolio to 30 positions during its lifetime. Issue closing 23 Feb. Arix Bioscience — Intention to float on the main market from the global healthcare and life science Company supporting medical innovation. Raised £52m in Feb 16 with investors including Woodford Investment Management